The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 15, MeiraGTx stock reached a 52-week high ahead of the pivotal Phase 1 data readout for AAV-hAQP1, aimed at treating radiation-induced xerostomia. Estimated peak sales for AAV2hAQP1 are approximately $1.2 billion.